Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (PKI) drives innovation in diagnostics, life sciences, and applied markets through advanced scientific solutions. This page aggregates official announcements and verified news about the company's strategic initiatives, financial performance, and technological advancements.
Investors and industry professionals will find timely updates on earnings reports, product launches, and regulatory milestones. Our curated collection simplifies tracking PKI's progress in enabling critical research and improving healthcare outcomes globally.
Key content includes updates on analytical instrumentation developments, partnership announcements with research institutions, and expansions in diagnostic testing capabilities. All materials adhere to strict factual reporting standards without speculative commentary.
Bookmark this page for streamlined access to PerkinElmer's latest corporate communications. Check back regularly for insights into how PKI continues to address complex challenges in scientific discovery and clinical diagnostics.
Revvity, Inc. (NYSE: RVTY) has released its annual Impact Report, showcasing the company's sustainability, social, and governance initiatives. Key highlights include:
- A 7% reduction in Scope 1 and 2 emissions in 2023
- Implementation of a sustainability due diligence program for suppliers
- 75% employee satisfaction with 85% participation in a survey
- Maintained 40% female representation in leadership positions
- Expanded gender pay gap analysis
- Introduction of new corporate policies on ethical AI, sustainable procurement, and cyber risk management
- Creation of Revvity Access STEM Scholarships
CEO Prahlad Singh emphasized the company's commitment to creating a healthier, cleaner, and more inclusive world through innovative solutions and sustainability initiatives.
Revvity, Inc. (NYSE: RVTY) has announced its plans to release third quarter 2024 financial results before the market opens on Monday, November 4, 2024. The company will host a conference call at 8:00 a.m. ET on the same day to discuss these results. Prahlad Singh, president and CEO, and Max Krakowiak, CFO, will lead the conference call. Investors can access a live audio webcast of the call through the Investors section of Revvity's website.
Revvity (NYSE: RVTY) has announced the launch of the EURORealTime APOE assay, an in-vitro diagnostic test for APOE genotyping in European countries accepting the CE mark. This test is important for assessing a patient's risk of side effects before starting anti-amyloid therapy for Alzheimer's disease.
The assay allows simultaneous detection of the three most frequent APOE forms (E2, E3, and E4), with E4 carriers having the highest risk for ARIA (Amyloid-Related Imaging Abnormalities) under therapy. The test requires only one reaction using genomic DNA from a single blood sample and can be automated on Revvity instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms.
This new solution will enable clinicians to take a more personalized approach in anti-amyloid treatment for Alzheimer's patients by providing additional patient information through APOE genotyping.
Revvity (NYSE: RVTY) has announced its participation in two upcoming investor conferences in September 2024. The company will present at the 2024 Wells Fargo Healthcare Conference in Boston on September 4, with CFO Max Krakowiak speaking at 8:45 a.m. ET. Additionally, Revvity will attend the 2024 Baird Global Healthcare Conference in New York City on September 10, where Steve Willoughby, SVP of investor relations, ESG, and risk, will present at 12:15 p.m. ET.
Both presentations will provide updates on Revvity's strategic priorities and will be available via live audio webcasts on the company's website. Replays will be accessible for at least 30 days after the events on the Revvity Investor Relations website.
Revvity reported Q2 2024 financial results with revenue of $692 million, down 2% reported and 1% organic. GAAP EPS was $0.45, up from $0.28 year-over-year, while adjusted EPS from continuing operations was $1.22, slightly up from $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80.
Segment performance varied: Life Sciences revenue decreased 7% to $314 million, with adjusted operating margin at 35.8%. Diagnostics revenue increased 1% to $378 million, with adjusted operating margin improving to 25.9%. Revvity updated its full-year revenue guidance to $2.77-$2.79 billion, assuming 2% organic growth.
Revvity's Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. This dividend will be paid on November 8, 2024, to shareholders of record at the close of business on October 18, 2024. Revvity, traded on the New York Stock Exchange under the ticker symbol RVTY, continues its practice of rewarding shareholders through regular dividend payments. This announcement demonstrates the company's commitment to providing consistent returns to its investors, even as it navigates the current economic landscape.
Revvity (NYSE: RVTY) will announce its Q2 2024 financial results on July 29, 2024, before the market opens. A conference call hosted by CEO Prahlad Singh and CFO Max Krakowiak will follow at 8:00 a.m. ET to discuss the results. Investors can access the live audio webcast via the company's website.
Revvity (NYSE: RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on June 10, 2024, at 8:00 a.m. ET in Miami, FL. The event will feature Prahlad Singh, the president and CEO of Revvity, who will provide an update on the company's strategic priorities. A live audio webcast and a replay of the presentation will be available on the company's website.